$QNRX
Quoin Pharmaceuticals, Ltd. Stock $qnrx

$qnrx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000141057824000198 Filed on March 14, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.385M	$6.071M
YoY Change	-5.95%	-7.81%
% of Gross Profit
Research & Development	$832.4K	$3.308M
YoY Change	35.77%	23.76%
% of Gross Profit
Depreciation & Amortization	$25.68K	$103.7K
YoY Change	-1.27%	-0.32%
% of Gross Profit
Operating Expenses	$2.218M	$9.379M
YoY Change	6.32%	1.3%
Operating Profit
YoY Change
Interest Expense	$167.8K	$691.9K
YoY Change	97.47%	-212.14%
% of Operating Profit
Other Income/Expense, Net	$0.00	$691.9K
YoY Change		-658.95%
Pretax Income	-$2.050M	-$8.687M
YoY Change	2.44%	-7.41%
Income Tax
% Of Pretax Income
Net Earnings	-$2.050M	-$8.687M
YoY Change	2.44%	-7.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.19	-$9.64
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.69M	$10.69M
YoY Change	-16.79%	-16.79%
Cash & Equivalents	$2.400M
Short-Term Investments	$8.294M	$8.294M
Other Short-Term Assets	$591.0K	$591.0K
YoY Change	14.41%	14.41%
Inventory
Prepaid Expenses	$591.0K
Receivables
Other Receivables
Total Short-Term Assets	$11.29M	$11.29M
YoY Change	-15.59%	-15.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$583.3K
YoY Change	-17.21%
Long-Term Investments
YoY Change
Other Assets	$300.0K	$300.0K
YoY Change	-21.75%	-21.75%
Total Long-Term Assets	$883.3K	$883.3K
YoY Change	-18.81%	-18.81%
TOTAL ASSETS
Total Short-Term Assets	$11.29M	$11.29M
Total Long-Term Assets	$883.3K	$883.3K
Total Assets	$12.17M	$12.17M
YoY Change	-15.83%	-15.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$526.5K	$526.5K
YoY Change	-13.06%	-13.06%
Accrued Expenses	$1.309M	$2.455M
YoY Change	11.31%	5.73%
Deferred Revenue
YoY Change
Short-Term Debt	$600.0K	$600.0K
YoY Change	0.0%	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.581M	$3.581M
YoY Change	1.53%	1.53%
LONG-TERM LIABILITIES
Long-Term Debt	$2.924M	$2.924M
YoY Change	-17.03%	-17.03%
Other Long-Term Liabilities	$2.924M
YoY Change	-17.03%
Total Long-Term Liabilities	$2.924M	$2.924M
YoY Change	-17.03%	-17.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.581M	$3.581M
Total Long-Term Liabilities	$2.924M	$2.924M
Total Liabilities	$6.505M	$6.505M
YoY Change	-7.74%	-7.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$46.20M
YoY Change	23.15%
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.664M	$5.664M
YoY Change
Total Liabilities & Shareholders Equity	$12.17M	$12.17M
YoY Change	-15.83%	-15.83%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.050M	-$8.687M
YoY Change	2.44%	-7.41%
Depreciation, Depletion And Amortization	$25.68K	$103.7K
YoY Change	-1.27%	-0.32%
Cash From Operating Activities	-$3.224M	-$7.864M
YoY Change	65.97%	-7.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$2.644M	$2.188M
YoY Change		-122.11%
Cash From Investing Activities	$2.644M	$2.188M
YoY Change		-121.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-182.6K	5.217M
YoY Change	-59.14%	-62.76%
NET CHANGE
Cash From Operating Activities	-3.224M	-7.864M
Cash From Investing Activities	2.644M	2.188M
Cash From Financing Activities	-182.6K	5.217M
Net Change In Cash	-762.2K	-459.4K
YoY Change	-68.1%	-90.06%
FREE CASH FLOW
Cash From Operating Activities	-$3.224M	-$7.864M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2023Q4	us-gaap	Other Liability Noncurrent Related Party Type Extensible Enumeration OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2023Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2023Q4	us-gaap	Other Liability Noncurrent Related Party Type Extensible Enumeration OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001671502
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	Quoin Pharmaceuticals, Ltd.
CY2022Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2022Q4	us-gaap	Other Liability Noncurrent Related Party Type Extensible Enumeration OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	987220
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	403887
CY2023Q3	qnrx	Shares Owned Percentage SharesOwnedPercentage	0.00083
CY2023Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.67
CY2023	us-gaap	Impairment Of Intangible Asset Finite Lived Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#ResearchAndDevelopmentExpense
CY2022Q4	us-gaap	Other Liability Related Party Type Extensible Enumeration OtherLiabilityRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2022Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2022Q4	us-gaap	Other Liability Noncurrent Related Party Type Extensible Enumeration OtherLiabilityNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#OfficerMember
CY2023Q3	qnrx	Shares Owned Percentage SharesOwnedPercentage	0.00083
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37846
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	92-2593104
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	42127 Pleasant Forest Court
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ashburn
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20148
CY2023	dei	City Area Code CityAreaCode	703
CY2023	dei	Local Phone Number LocalPhoneNumber	980-4182
CY2023	dei	Security12b Title Security12bTitle	American Depositary Shares
CY2023	dei	Trading Symbol TradingSymbol	QNRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5800000
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2401198
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2860628
CY2023Q4	us-gaap	Investments Investments	8293663
CY2022Q4	us-gaap	Investments Investments	9992900
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	591034
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	516584
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11285895
CY2022Q4	us-gaap	Assets Current AssetsCurrent	13370112
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	300000
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	383390
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	583334
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	704561
CY2023Q4	us-gaap	Assets Assets	12169229
CY2022Q4	us-gaap	Assets Assets	14458063
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	526523
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	605600
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1308706
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1175705
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	1146251
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	1146251
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	600000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	600000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3581480
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3527556
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2923733
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3523733
CY2023Q4	us-gaap	Liabilities Liabilities	6505213
CY2022Q4	us-gaap	Liabilities Liabilities	7051289
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8333334
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	987220
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	403887
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2023	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	0
CY2022	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	45
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2932000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	51867336
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47855521
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46203320
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37516747
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5664016
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7406774
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12169229
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14458063
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6070517
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6584868
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3307987
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2672836
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9378504
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9257704
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	416000
CY2022	qnrx	Warrant Liability Income Expense Value WarrantLiabilityIncomeExpenseValue	-77237
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-2683
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1307
CY2023	qnrx	Realized And Accrued Interest Income RealizedAndAccruedInterestIncome	694614
CY2022	qnrx	Realized And Accrued Interest Income RealizedAndAccruedInterestIncome	95745
CY2022	qnrx	Increase In Accrued Interest And Financing Expenses IncreaseInAccruedInterestAndFinancingExpenses	714081
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	691931
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-123792
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8686573
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9381496
CY2022	qnrx	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	65266
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8686573
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9446762
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	657032
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-9381496
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	764007
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14877332
CY2022	qnrx	Stock Issued During Period Value Settlement Of Accrued Liabilities StockIssuedDuringPeriodValueSettlementOfAccruedLiabilities	193537
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	296362
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7406774
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8686573
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1094549
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5849266
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5664016
CY2023	us-gaap	Profit Loss ProfitLoss	-8686573
CY2022	us-gaap	Profit Loss ProfitLoss	-9381496
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-77237
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1094549
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	764007
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	416000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	103706
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104043
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	17521
CY2022	qnrx	Increase In Accrued Interest And Financing Expenses IncreaseInAccruedInterestAndFinancingExpenses	714081
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	489079
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	93779
CY2023	qnrx	Increase Decrease In Accounts Payable And Accrued Expenses IncreaseDecreaseInAccountsPayableAndAccruedExpenses	53924
CY2022	qnrx	Increase Decrease In Accounts Payable And Accrued Expenses IncreaseDecreaseInAccountsPayableAndAccruedExpenses	-217806
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-41523
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-123455
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7864429
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8480732
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	18090684
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9899121
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	20279000
CY2022	qnrx	Payments For Previous Intangible Asset Acquisition PaymentsForPreviousIntangibleAssetAcquisition	250000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2188316
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10149121
CY2023	qnrx	Payments For Proceeds From Deferred Loan Costs PaymentsForProceedsFromDeferredLoanCosts	32583
CY2022	qnrx	Payments For Proceeds From Deferred Loan Costs PaymentsForProceedsFromDeferredLoanCosts	-42045
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	600000
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	599999
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	311670
CY2023	qnrx	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	5849266
CY2022	qnrx	Net Proceeds From Issuance Of Common Stock NetProceedsFromIssuanceOfCommonStock	14877332
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5216683
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14007708
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-459430
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4622145
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2860628
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7482773
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2401198
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2860628
CY2022	qnrx	Reclassification Of Warrant Liability To Equity Upon Issuance Of Exchange Warrants ReclassificationOfWarrantLiabilityToEquityUponIssuanceOfExchangeWarrants	296362
CY2022	qnrx	Deemed Dividend On Warrant Modification DeemedDividendOnWarrantModification	65266
CY2023	qnrx	Offering Expenses Associated With Warrant Modification OfferingExpensesAssociatedWithWarrantModification	238231
CY2022	qnrx	Offering Expenses Associated With Warrant Modification OfferingExpensesAssociatedWithWarrantModification	491601
CY2022	qnrx	Settlement Of Accrued Liabilities SettlementOfAccruedLiabilities	193537
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	46200000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2400000
CY2023Q4	us-gaap	Investments Investments	8300000
CY2023Q3	qnrx	Number Of Shares Represented For One American Depositary Share NumberOfSharesRepresentedForOneAmericanDepositaryShare	60000
CY2023Q4	qnrx	Number Of Ordinary Shares For American Depositary Shares NumberOfOrdinarySharesForAmericanDepositaryShares	60000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: settlement of debt or other obligations, stock-based compensation, research and development expense recognition, intangible asset estimated useful lives and impairment assessments, allowances of deferred tax assets, and cash flow assumptions regarding going concern considerations.</p>
CY2023Q4	us-gaap	Trading Securities TradingSecurities	8300000
CY2022Q4	us-gaap	Trading Securities TradingSecurities	10000000.0
CY2023	qnrx	Investmentsmaturityterm Investmentsmaturityterm	P4M
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	1
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	32583
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	401972
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	508084
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8500
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8500
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	12000000.0
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	33333
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	491000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.106
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.060
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.048
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.027
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y10M24D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	6.62
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	210.00
CY2023	qnrx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of American Depositary Share ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAmericanDepositaryShare	4.31
CY2022	qnrx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of American Depositary Share ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfAmericanDepositaryShare	184.56
CY2023	qnrx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Estimated Fair Value Of Option ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsEstimatedFairValueOfOption	3.60
CY2022	qnrx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Estimated Fair Value Of Option ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsEstimatedFairValueOfOption	155.04
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1090000.00
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	764000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3.0
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y8M12D
CY2023Q4	qnrx	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	447979
CY2022Q4	qnrx	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	383390
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	891034
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	899974
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	591034
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	516584
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	300000
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	383390
CY2023Q4	qnrx	Accrued Research Contract Expense Current AccruedResearchContractExpenseCurrent	358287
CY2022Q4	qnrx	Accrued Research Contract Expense Current AccruedResearchContractExpenseCurrent	105071
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	804156
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	788169
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	93989
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	159593
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	50534
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	44278
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1740
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	78594
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1308706
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1175705
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3523733
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1000000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1040433
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	416666
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	335872
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	583334
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	704561
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	104000
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	18000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	100000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	100000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	100000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	100000
CY2023Q4	qnrx	Finite Lived Intangible Assets Amortization After Year Four FiniteLivedIntangibleAssetsAmortizationAfterYearFour	183000
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	3523733
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	4123732
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	600000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	600000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2923733
CY2022Q3	qnrx	Shares Owned Percentage SharesOwnedPercentage	0.125
CY2023Q4	qnrx	Number Of Ordinary Shares For American Depositary Shares NumberOfOrdinarySharesForAmericanDepositaryShares	500000000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	qnrx	Number Of Ordinary Shares For American Depositary Shares NumberOfOrdinarySharesForAmericanDepositaryShares	6000000000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Treasury Stock Shares Retired TreasuryStockSharesRetired	45
CY2023Q4	qnrx	Number Of Years Income For Distribution Limit NumberOfYearsIncomeForDistributionLimit	2
CY2023	qnrx	Date Of Financial Statements And Distribution Period Maximum DateOfFinancialStatementsAndDistributionPeriodMaximum	P6M
CY2023Q4	qnrx	Number Of Years Income For Distribution Limit NumberOfYearsIncomeForDistributionLimit	2
CY2022Q3	qnrx	Stock Issued During Period Shares Settlement Of Accrued Liabilities StockIssuedDuringPeriodSharesSettlementOfAccruedLiabilities	3682
CY2023Q1	qnrx	Aggregate Gross Proceeds From Issuance Offering AggregateGrossProceedsFromIssuanceOffering	7000000.0
CY2023Q1	qnrx	Net Proceeds From Issuance Offering NetProceedsFromIssuanceOffering	5800000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	664.68
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	597.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	64.20
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.13
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4276000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3334000
CY2023Q4	qnrx	Deferred Tax Assets Tax Deferred Expense Accrued Expenses And Other DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther	175000
CY2022Q4	qnrx	Deferred Tax Assets Tax Deferred Expense Accrued Expenses And Other DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther	189000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	321000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	76000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	289000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	178000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1104000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	581000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	51000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	34000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6216000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4392000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6216000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4392000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1824000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1970000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	167000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	153000
CY2023	qnrx	Effective Income Tax Rate Reconciliation Research And Development Amount EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentAmount	-195000
CY2022	qnrx	Effective Income Tax Rate Reconciliation Research And Development Amount EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentAmount	-76000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	79000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	388000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1824000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	347000
CY2023	qnrx	Effective Income Tax Rate Reconciliation Deferred True Up Amount EffectiveIncomeTaxRateReconciliationDeferredTrueUpAmount	-51000
CY2022	qnrx	Effective Income Tax Rate Reconciliation Deferred True Up Amount EffectiveIncomeTaxRateReconciliationDeferredTrueUpAmount	1158000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6216000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4392000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	qnrx	Deferred Tax Asset Capitalization Of Research And Development Costs DeferredTaxAssetCapitalizationOfResearchAndDevelopmentCosts	4617000
CY2023	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NOTE 16 - CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may become involved in various legal matters arising in the ordinary course of business. Management is unaware of any matters requiring accrual for related losses in the financial statements.</p>
CY2023	qnrx	Number Of License And Supply Agreements Entered NumberOfLicenseAndSupplyAgreementsEntered	9
CY2022	qnrx	Number Of License And Supply Agreements Entered NumberOfLicenseAndSupplyAgreementsEntered	8
CY2023	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	0

Files In Submission

Name	View Source	Status
0001410578-24-000198-index-headers.html	Edgar Link	pending
0001410578-24-000198-index.html	Edgar Link	pending
0001410578-24-000198.txt	Edgar Link	pending
0001410578-24-000198-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qnrx-20231231.xsd	Edgar Link	pending
qnrx-20231231x10k.htm	Edgar Link	pending
qnrx-20231231xex23d1.htm	Edgar Link	pending
qnrx-20231231xex31d1.htm	Edgar Link	pending
qnrx-20231231xex31d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qnrx-20231231x10k_htm.xml	Edgar Link	completed
qnrx-20231231xex32d1.htm	Edgar Link	pending
qnrx-20231231xex32d2.htm	Edgar Link	pending
qnrx-20231231xex4d19.htm	Edgar Link	pending
qnrx-20231231xex97d1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
qnrx-20231231_pre.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
qnrx-20231231_def.xml	Edgar Link	unprocessable
qnrx-20231231_cal.xml	Edgar Link	unprocessable
qnrx-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QNRX
Quoin Pharmaceuticals, Ltd. Stock $qnrx

2023 Q4 Form 10-K Financial Statement

#000141057824000198 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QNRX Quoin Pharmaceuticals, Ltd. Stock $qnrx

2023 Q4 Form 10-K Financial Statement

#000141057824000198 Filed on March 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QNRX
Quoin Pharmaceuticals, Ltd. Stock $qnrx